Zelira Therapeutics (OTC:ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is about to begin a first-ever clinical trial of its own proprietary pain formula for the treatment of diabetic nerve pain against an as-yet-unidentified brand name pain medication, the company announced.
The trial will evaluate the efficacy, safety and tolerability of Zelira’s patent-protected product.
